Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123239
Filing Date
2024-11-07
Accepted
2024-11-07 16:00:28
Documents
68
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vera-20240930.htm   iXBRL 10-Q 2331289
2 EX-10.2 vera-ex10_2.htm EX-10.2 331804
3 EX-31.1 vera-ex31_1.htm EX-31.1 15983
4 EX-31.2 vera-ex31_2.htm EX-31.2 15952
5 EX-32.1 vera-ex32_1.htm EX-32.1 9449
6 EX-32.2 vera-ex32_2.htm EX-32.2 9651
  Complete submission text file 0000950170-24-123239.txt   8367865

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vera-20240930.xsd EX-101.SCH 1096652
71 EXTRACTED XBRL INSTANCE DOCUMENT vera-20240930_htm.xml XML 1238933
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40407 | Film No.: 241435341
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)